 |
|
MR imaging helps predict recurrence in prostate cancer patients
May 07, 2007MR images taken of prostate cancer patients prior to treatment that show that the cancer has spread outside the prostate gland capsule help predict whether the cancer will return, according to a recent study conducted by radiologists at the University of California-San Francisco.
The study consisted of 74 men with biopsy-proven prostate cancer who underwent endorectal MR imaging of the prostate, said Antonio Westphalen, MD, lead author of the study. Tumor size, stage and extracapsular extension (cancer spread outside the prostate gland capsule) were all recorded.
"The study focused on patients who were treated with radiation therapy, more specifically, external beam radiation therapy, which is the treatment of choice of about one-third of patients with newly diagnosed prostate cancer," said Dr. Westphalen.
After a follow-up of an average 42 months, four patients developed metastases - all four had extracapsular extension seen on MR imaging before treatment, Dr. Westphalen said. Three of them had more than 5mm of extracapsular extension at MR imaging, he said.
"The main goal of our study was to identify features on our imaging that would predict treatment failure, perhaps allowing for a more conscientious decision ahead of time. We found that a subset of patients who presented with imaging signs of extracapsular extension prior to radiation were more likely to develop metastases in the future," said Dr. Westphalen.
The full results of the study will be presented on Tuesday, May 8, 2007 during the American Roentgen Ray Society Annual Meeting in Orlando, FL.
American Roentgen Ray Society
After a follow-up of an average 42 months, four patients developed metastases - all four had extracapsular extension seen on MR imaging before treatment, Dr. Westphalen said. Three of them had more than 5mm of extracapsular extension at MR imaging, he said.
"The main goal of our study was to identify features on our imaging that would predict treatment failure, perhaps allowing for a more conscientious decision ahead of time. We found that a subset of patients who presented with imaging signs of extracapsular extension prior to radiation were more likely to develop metastases in the future," said Dr. Westphalen.
The full results of the study will be presented on Tuesday, May 8, 2007 during the American Roentgen Ray Society Annual Meeting in Orlando, FL.
American Roentgen Ray Society
Prostate Cancer Current Events and Prostate Cancer News RSSNew Catheter-less Technique May Ease the Pain and Discomfort of Prostate Cancer Recovery
To ease the pain of recovery following prostate cancer surgery, physician-scientists have developed an innovative and patient-friendly approach that eliminates the use of a penile urinary catheter.
Racial disparities decline for cancer in Missouri
Cancer death rates in the United States are highest among African Americans, but a new report shows that in Missouri the disparity in cancer incidence and death between African Americans and whites is declining.
OHSU Cancer Institute researchers study breathing during radiation
Oregon Health & Science University researchers have determined exactly how much breathing affects prostate movement during radiation treatment.
Hormone therapy before radiation seed implants for prostate cancer
Men over 70 years of age with early-stage prostate cancer have 20 percent higher mortality if they are treated first with hormone therapy before being treated with radiation seed implants (brachytherapy), compared to men who are treated with brachytherapy alone.
Newly found gene variants account for kidney diseases among African-Americans
For the first time, researchers have identified variations in a single gene that are strongly associated with kidney diseases disproportionately affecting African-Americans. This work was conducted by researchers at the National Institutes of Health (NIH) and by NIH-funded investigators at the Johns Hopkins University.
Common painkillers lower levels of prostate cancer biomarker
Common painkillers like aspirin and ibuprofen appear to lower a man's PSA level, the blood biomarker widely used by physicians to help gauge whether a man is at risk of prostate cancer.
Anti-inflammatory drugs may mask prostate cancer marker
Regular use of nonsteroidal anti-inflammatory drugs (NSAIDs), such as aspirin and ibuprofen, may reduce serum levels of the prostate biomarker, PSA (prostate specific antigen), and hence may alter the detection of prostate cancer in individuals who take these medications.
Too much calcium in blood may increase risk of fatal prostate cancer
Men who have too much calcium in their bloodstreams may have an increased risk of fatal prostate cancer, according to a new analysis from Wake Forest University School of Medicine and the University of Wisconsin.
Height linked to risk of prostate cancer development and progression
A man's height is a modest marker for risk of prostate cancer development, but is more strongly linked to progression of the cancer, say British researchers who conducted their own study on the connection and also reviewed 58 published studies.
Health risk behaviors associated with lower prostate specific antigen awareness
According to a study conducted at Columbia University Mailman School of Public Health, health risk behaviors such as smoking and obesity are associated with lower awareness of the Prostate Specific Antigen (PSA), which could lead to a lower likelihood of undergoing actual prostate cancer screening.
More Prostate Cancer Current Events and Prostate Cancer News Articles
| © 2008 BrightSurf.com |